DNA-HIV-PT123 vaccine(National Institute of Allergy & Infectious Diseases)(DNA-HIV-PT123 vaccine(National Institute of Allergy & Infectious Diseases))

概要

基本信息

药物类型

DNA疫苗、预防性疫苗

别名-

靶点-

作用机制

免疫刺激剂

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症

HIV感染

非在研适应症-

原研机构

National Institute of Allergy & Infectious Diseases

在研机构

National Institute of Allergy & Infectious Diseases

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

6

项与 DNA-HIV-PT123 vaccine(National Institute of Allergy & Infectious Diseases) 相关的临床试验

NCT02915016 / Completed临床1/2期IIT

A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DNA, and of MF59®- or AS01B-Adjuvanted Clade C Env Protein in Various Combinations, in Healthy, HIV-Uninfected Adult Participants

This study will evaluate the safety and immune response to the DNA-HIV-PT123 vaccine used in combination with one of two protein vaccines (Bivalent Subtype C gp120/MF59 or Bivalent Subtype C gp120/AS01B) in healthy, HIV-uninfected adults.

开始日期2016-12-07

申办/合作机构

National Institute of Allergy & Infectious Diseases

NCT02997969 / Completed临床1期IIT

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DNA and of MF59-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants

The purpose of this study is to evaluate the safety and immune response to an HIV clade C DNA vaccine and to an MF59-adjuvanted clade C Env protein in healthy, HIV-uninfected adults.

开始日期2016-06-21

申办/合作机构

National Institute of Allergy & Infectious Diseases

[+2]

NCT02207920 / Completed临床1期IIT

A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants

This study will evaluate the safety, tolerability, and immune response to different combinations of two experimental HIV vaccines-the DNA-HIV-PT123 vaccine and the AIDSVAX® B/E vaccine-in healthy adults who are not infected with HIV.

开始日期2014-07-01

申办/合作机构

National Institute of Allergy & Infectious Diseases

100 项与 DNA-HIV-PT123 vaccine(National Institute of Allergy & Infectious Diseases) 相关的临床结果

登录后查看更多信息

100 项与 DNA-HIV-PT123 vaccine(National Institute of Allergy & Infectious Diseases) 相关的转化医学

登录后查看更多信息

100 项与 DNA-HIV-PT123 vaccine(National Institute of Allergy & Infectious Diseases) 相关的专利（医药）

登录后查看更多信息

100 项与 DNA-HIV-PT123 vaccine(National Institute of Allergy & Infectious Diseases) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HIV感染	临床2期	美国	National Institute of Allergy & Infectious Diseases	2016-12-07
HIV感染	临床2期	南非	National Institute of Allergy & Infectious Diseases	2016-12-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02915016 (HVTN108, CTgov)	临床1/2期	HIV感染	334	Placebo+DNA-HIV-PT123 vaccine+Bivalent Subtype C gp120/MF59 vaccine (Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59)	鏇積鏇艱廠蓋齋遞鹹艱(遞獵觸夢襯顧網窪鹽夢) = 選觸膚艱糧鑰鬱獵醖鏇淵構築糧齋壓壓鑰顧積 (憲範餘淵齋蓋鏇顧鏇膚, 願築觸醖壓淵淵製鏇憲 ~ 觸獵醖製蓋窪獵膚鬱遞) 更多	-	2020-09-16
				Placebo+Bivalent Subtype C gp120/AS01B vaccine+DNA-HIV-PT123 vaccine (Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B)	鏇積鏇艱廠蓋齋遞鹹艱(遞獵觸夢襯顧網窪鹽夢) = 憲鑰憲夢範膚築餘窪築淵構築糧齋壓壓鑰顧積 (憲範餘淵齋蓋鏇顧鏇膚, 觸築憲憲膚繭願鏇鏇遞 ~ 廠襯鏇鹽醖製廠繭襯窪) 更多